Skip to content

All Sections

Thursday, March 19th 2026

Today's E-Edition

Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
Branded Content
- Paid Content by Brandpoint
SUBSCRIBE NOW

Sign up for email newsletters

Subscribe

Account Settings Contact Us Log Out

Spoof a user

Sign up for email newsletters

Subscribe

Silicon Valley

Thursday, March 19th 2026

Today's E-Edition

Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News

Create Watchlist

Nasdaq Composite

Silicon Valley 150

Markets:

News

Articles published by Zealand Pharma

< Previous 1 2 3 4 Next >

Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank

December 22, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma to highlight obesity pipeline at R&D Event on December 5

December 04, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers

November 30, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma Announces Financial Results for the First Nine Months of 2023

November 09, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023

November 07, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results

November 03, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek

October 17, 2023

From Zealand Pharma

Via GlobeNewswire

Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease

October 05, 2023

From Zealand Pharma

Via GlobeNewswire

SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023

September 08, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma to participate in upcoming healthcare conferences in September 2023

September 07, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism

August 30, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma Announces Financial Results for the First Half of 2023

August 17, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results

August 14, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396

July 03, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism

June 30, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions

June 24, 2023

From Zealand Pharma

Via GlobeNewswire

Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)

June 23, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma Announces Financial Results for the First Quarter of 2023

May 11, 2023

From Zealand Pharma

Via GlobeNewswire

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight

May 10, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 Results

May 04, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference

April 12, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion

March 30, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma announces directed issue and private placement of approximately 6.5 million new shares

March 30, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396

March 28, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

March 09, 2023

From Zealand Pharma

Via GlobeNewswire

Correction: Zealand Pharma convenes its Annual General Meeting 2023

March 03, 2023

From Zealand Pharma

Via GlobeNewswire

News headline image

Correction: Zealand Pharma Announces Full Year Results for 2022

March 02, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma convenes its Annual General Meeting 2023

March 02, 2023

From Zealand Pharma

Via GlobeNewswire

News headline image

Zealand Pharma Announces Full Year Results for 2022

March 02, 2023

From Zealand Pharma

Via GlobeNewswire

Zealand Pharma to Host Conference Call on March 2, 2023 at 2 pm CET (8 am ET) to Present Full Year Results for 2022

February 24, 2023

From Zealand Pharma

Via GlobeNewswire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.

News Alerts
Member Services
Contact Us
Marketplace
- Real Estate
- Lottery
Classifieds
Subscribe Now

Terms of Use
Accessibility
Cookie Policy
Cookie Preferences
California Notice at Collection
Notice of Financial Incentive
Do Not Sell/Share My Personal Information
Arbitration
Powered by WordPress.com VIP

Copyright 2026 Silicon Valley. All rights reserved. The use of any content on this website for the purpose of training artificial intelligence systems, algorithms, machine learning models, text and data mining, or similar use is strictly prohibited without explicit written consent.